WASHINGTON, July 10 — For the millions of American families touched by Alzheimer’s disease, the conversation around treatment has shifted from managing symptoms to something far more profound: the possibility of slowing the disease itself. That shift is now colliding with the hard calculus of cost, access, and a healthcare system bracing for what could be a seismic financial shift. New disease-modifying therapies have entered the market, and with them, projections of a drug market that could nearly triple in size by the end of the decade.
According to a 2023 report from GlobalData, the global Alzheimer’s drug market was valued at roughly $5.6 billion in 2022. By 2030, analysts project it could reach $15 billion.
The engine of that growth is a new class of treatments — the first to target the underlying biology of the disease rather than just its outward symptoms.
A new class of drugs, a new set of questions
Two drugs have captured the most attention. Eisai and Biogen’s lecanemab generated $4.7 million in sales in the third quarter of 2023. Industry analysts project its peak annual sales could land between $10 billion and $15 billion.
Eli Lilly’s donanemab, if approved, is forecast to reach peak sales of $8 billion to $10 billion. These are not small numbers.
They reflect a genuine medical breakthrough — the first time any treatment has been shown to modify the course of Alzheimer’s rather than simply mask its symptoms. For patients and their families, this represents a real change in the landscape of hope. But hope, in the American healthcare system, comes with a price tag.
The cost of treatment, the burden on patients
Lecanemab carries an annual list price of $26,500 per patient. That figure has already raised concerns among policymakers and patient advocates about affordability and the strain it could place on the healthcare system. Medicare covers 80 percent of the drug cost.
That leaves patients responsible for a 20 percent coinsurance. The broader economic context is sobering.
The total economic burden of Alzheimer’s in the United States was estimated at $345 billion in 2023. That figure includes direct medical costs and the imputed value of unpaid caregiving provided by family members — the spouses, adult children, and neighbors who spend countless hours providing care that the formal system does not cover.
What a delay could mean — in lives and dollars
A 2020 study by the Alzheimer’s Association offered a striking glimpse of what successful treatment could mean at a population level. The study estimated that if researchers could find a way to delay the onset of Alzheimer’s by five years, the savings in healthcare costs by 2050 would reach $1.1 trillion. That is not a cure — it is a delay.
But even a modest postponement of the disease’s relentless progression would fundamentally alter the trajectory of the epidemic, sparing millions of families the most devastating years of decline and saving the system enormous sums in avoided care. The challenge lies in translating that potential into reality.
Lecanemab and donanemab are not cures. They are disease-modifying therapies, meaning they slow progression but do not reverse damage already done. They require regular intravenous infusions, close monitoring for side effects including brain swelling and bleeding, and early diagnosis — something the healthcare system is still not well equipped to deliver at scale.
The road ahead
As of mid-2026, the landscape continues to evolve. Eli Lilly’s donanemab has yet to receive full approval, though expectations remain high. The broader market is watching closely, not only for regulatory decisions but for data on real-world effectiveness and safety.
Meanwhile, the question of access looms large. Will Medicare and private insurers impose strict coverage criteria?
Will the infrastructure of infusion centers and specialist clinics be able to handle the demand? And what about the millions of patients who are diagnosed too late to benefit from these treatments? The answers are not yet clear.
What is clear is that the Alzheimer’s drug market has entered a new era — one defined not just by the science of what is possible, but by the economics of what is sustainable. For the families navigating this disease day by day, those two questions are inseparable.
{“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Alzheimer’s Drug Market Projected to Hit $15 Billion by 2030”, “description”: “WASHINGTON, July 10 — For the millions of American families touched by Alzheimer’s disease, the conversation around treatment has shifted from managing symptoms to something…”, “datePublished”: “2026-07-10T09:30:00+00:00”, “author”: {“@type”: “Person”, “name”: “James Roberto”}, “publisher”: {“@type”: “Organization”, “name”: “InfoPulse Today”, “url”: “https://newsfeed.infopulsetoday.com/”}}
